Download MendeleyImplementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors.
Parr, B.T., Pastor, R., Sellers, B.D., Pei, Z., Jaipuri, F.A., Castanedo, G.M., Gazzard, L., Kumar, S., Li, X., Liu, W., Mendonca, R., Pavana, R.K., Potturi, H., Shao, C., Velvadapu, V., Waldo, J.P., Wu, G., Yuen, P.W., Zhang, Z., Zhang, Y., Harris, S.F., Oh, A.J., DiPasquale, A., Dement, K., La, H., Goon, L., Gustafson, A., VanderPorten, E.C., Mautino, M.R., Liu, Y.(2020) ACS Med Chem Lett 11: 541-549
- PubMed: 32292562
- DOI: https://doi.org/10.1021/acsmedchemlett.0c00004
- Primary Citation of Related Structures:
6VBN - PubMed Abstract:
A class of imidazoisoindole (III) heme-binding indoleamine-2,3-dioxygenase (IDO1) inhibitors were optimized via structure-based drug design into a series of tryptophan-2,3-dioxygenase (TDO)-selective inhibitors. Kynurenine pathway modulation was demonstrated in vivo , which enabled evaluation of TDO as a potential cancer immunotherapy target. As means of mitigating the risk of drug-drug interactions arising from cytochrome P450 inhibition, a novel property-based drug design parameter, herein referred to as the CYP Index, was implemented for the design of inhibitors with appreciable selectivity for TDO over CYP3A4. We anticipate the CYP Index will be a valuable design parameter for optimizing CYP inhibition of any small molecule inhibitor containing a Lewis basic motif capable of binding heme.
Organizational Affiliation:
Genentech, South San Francisco, California 94080, United States.
